CYCN vs GS · $8.6M cap vs P/E 20, rev $37.56B
Cyclerion Therapeutics Inc (CYCN) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
Cyclerion Therapeutics Inc (CYCN) is a biotechnology company listed on US.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Latest reported CYCN revenue for 2026-06-30 was $0. Net income was -$4.9M. CYCN currently screens at market cap $8.6M.
Latest reported GS revenue for 2026-06-30 was $37.56B. Net income was $12.26B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
CYCN currently screens at market cap $8.6M. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the CYCN and GS stock pages for the full models.
Not investment advice.